Shares of Lexicon Pharmaceuticals LXRX increased in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share rose 76.19% over the past year to ($0.15), which beat the estimate of ($0.16).
Revenue of $27,000 decreased by 99.66% from the same period last year, which missed the estimate of $1,680,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: May 06, 2021
Time: 05:00 PM
ET Webcast URL: https://www.lexpharma.com/investors
Technicals
Company's 52-week high was at $9.65
Company's 52-week low was at $1.03
Price action over last quarter: down 35.45%
Company Profile
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
